Starting news article english 27 January 2012

Clifford Chance advises Amgen on its acquisition of Micromet

Amgen, Inc. and Micromet, Inc. announced today that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development center in Munich and headquarters in Rockville, MD., for USD 11 per share in cash. The transaction, which values Micromet at approx. USD 1,1 billion was unanimously approved by both the Amgen and Micromet boards of directors.

The acquisition includes blinatumomab, a specific T cell engager (BiTE®) antibody in phase two clinical development for acute lymphoblastic leukemia.

Clifford Chance acted as local counsel in Germany on the transaction. The team, led by Dr. Peter Dieners, comprised partner Dr. Thomas Stohlmeier, counsel Dr. Christian Vogel and associate Bernd Steffes-mies (all Corporate, Düsseldorf), partner Dr. Claudia Milbradt, senior associate Dr. Wolfgang Schönig and Anja Schwarz (all IP, Düsseldorf), partner Thomas Hey, senior associate Johannes Simon and associate Philipp Schäuble (all Employment Law, Düsseldorf), partner Dr. Uwe Schimmelschmidt (Tax, Frankfurt) and senior associate Cord von Mandelsloh (Tax, Düsseldorf) as well as counsel Dr. Ulrich Flege (Real Estate, Düsseldorf) and senior associate Marc Oeben (Compliance/Regulatory, Düsseldorf).